Abstract
Objective
The objective of this study was to characterize the dose-volume relationship of small bowel toxicity during prostate radiation therapy in a homogenous Veterans Affairs population using modern IMRT/VMAT radiation techniques.
Methods
All records of patients receiving radiation therapy for prostate cancer at the Veterans Affairs Long Beach Hospital between 2009 and 2011 were analyzed (n = 73). Peritoneal space contents were contoured on each slice of the planning CT scan. A median dose of 75.6 Gy was delivered with either intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT). The small bowel constraint used was V45 < 200 cc. Median follow-up was 2.4 years. Toxicity was scored using CTCAE v4.0 to grade acute and late small bowel toxicity.
Results
Seventeen patients (23 %) experienced acute grade 1 small bowel toxicity. Twenty-seven patients (37 %) experienced acute grade 2 small bowel toxicity. There was 3 % grade 1 and 10 % grade 2 late small bowel toxicity. There was no grade 3 or higher acute or late bowel toxicity. The mean volume of a small bowel receiving a dose of 45 Gy was 58 cc, range (2–193 cc). Nineteen patients (26 %) received greater than 52 Gy, range (52–80 Gy) and had no late small bowel toxicity. Multivariate analysis showed that prior abdominal surgery predicted acute small bowel toxicity HR = 4.6 (95 % CI 1.24–20.5) p = 0.03.
Conclusion
In this Veterans Affairs population of prostate cancer patients treated with radiation, V45 < 200 cc minimizes small bowel toxicity. However, we show this constraint can possibly be exceeded without significant short- and long-term complications. Further studies should explore maximum tolerated dose-volume relationship to maximize tumor control without increasing the small bowel toxicity profile.
Similar content being viewed by others
References
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin
Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ (2011) Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 117(7):1429–1437
Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK, RT01 collaborators (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487
Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV (2014) Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 110(1):104–109
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74
Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233–1239
Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368(5):436–445
Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z (2005) Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63(3):765–771
Arcangeli S, Saracino B, Petrongari MG, Gomellini S, Marzi S, Landoni V, Gallucci M, Sperduti I, Arcangeli G (2007) Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 84(2):148–155
Cozzarini C, Fiorino C, Di Muzio N, Alongi F, Broggi S, Cattaneo M, Montorsi F, Rigatti P, Calandrino R, Fazio F (2007) Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol 84(2):164–170
Muren LP, Wasbø E, Helle SI, Hysing LB, Karlsdottir A, Odland OH, Valen H, Ekerold R, Johannessen DC (2008) Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences. Int J Radiat Oncol Biol Phys 71(4):1034–1041
Sanguineti G, Endres EJ, Parker BC, Bicquart C, Little M, Chen G, Berilgen J (2008) Acute toxicity of wholepelvis IMRT in 87 patients with localized prostate cancer. Acta Oncol 47(2):301–310
Fiorino C, Alongi F, Perna L, Broggi S, Cattaneo GM, Cozzarini C, Di Muzio N, Fazio F, Calandrino R (2009) Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 75(1):29–35
Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M (2009) RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74(2):383–387
Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, Miften M (2010) Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 76(3 Suppl):S101–S107
Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340(15):1154–1161
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730
Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114–1123
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974
Team R.C (2014) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
Gallagher MJ, Brereton HD, Rostock RA, Zero JM, Zekoski DA, Poyss LF, Richter MP, Kligerman MM (1986) A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 12(9):1565–1573
Huang EY, Hsu HC, Yang KD, Lin H, Wang FS, Sun LM, Tsai CC, Changchien CC, Wang CJ (2005) Acute diarrhea during pelvic irradiation: is small-bowel volume effect different in gynecologic patients with prior abdomen operation or not? Gynecol Oncol 97(1):118–125
Compliance with ethical standards
For this type of study, formal consent is not required. This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Green, G., Lin, A.J., Zhang, J. et al. Dose-volume relationship of acute and late small bowel toxicity from radiation therapy for prostate cancer: a Veterans Affairs study. J Radiat Oncol 4, 411–415 (2015). https://doi.org/10.1007/s13566-015-0205-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13566-015-0205-8